Heat shock protein 90 inhibitors repress latent membrane protein 1 (LMP1) expression and proliferation of Epstein-Barr virus-positive natural killer cell lymphoma.
Where this comes from
- Record sourced from PubMed, PMID 23658841.
- Also identified by DOI 10.1371/journal.pone.0063566 and PMC identifier 3643901.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Epstein-Barr virus (EBV) LMP1 is a major oncoprotein expressed in latent infection. It functions as a TNFR family member and constitutively activates cellular signals, such as NFκB, MAPK, JAK/STAT and AKT. We here screened small molecule inhibitors and isolated HSP90 inhibitors, Radicicol and 17-AAG, as candidates that suppress LMP1 expression and cell proliferation not only in EBV-positive SNK6 Natural Killer (NK) cell lymphoma cells, but also in B and T cells. Tumor formation in immuno-defficient NOD/Shi-scid/IL-2Rγ(null) (NOG) mice was also retarded. These results suggest that HSP90 inhibitors can be alternative treatments for patients with EBV-positive malignancies.
Medical subject headings
- Antineoplastic Agents
- Benzoquinones
- Epstein-Barr Virus Infections
- HSP90 Heat-Shock Proteins
- Lactams, Macrocyclic
- Lymphoma
- Macrolides
- Small Molecule Libraries
- Viral Matrix Proteins